Focus on innovative research and development of biomaterial surface modification technology, and develop high-end functional coating products with independent intellectual property rights and international competitiveness.
Venture capital learned that on April 15, Jiangsu baisaifei Biotechnology Co., Ltd. (hereinafter referred to as “baisaifei”) announced that it had completed a round B financing of more than 100 million yuan. The current round of financing is led by Huatai Zijin, an investment platform affiliated to Huatai Securities, a strategic investor, and the capital increase of jiuzhao investment, an old shareholder, followed by Guoqian venture capital, Hongyuan investment, Suzhou Industrial Park Science and innovation fund and other institutions.
This round of financing will be mainly used to accelerate the continuous layout of besafel in the field of functional coating products of high-end medical devices, promote the high-tech R & D and achievement transformation in the field of IVD and high-end biomedical consumables, improve the supervision, scientific research, inspection and testing service level of functional coating medical devices, and support the construction of production base in Changshu Suyu biomedical industrial park.
Besafel is a technical service provider for the whole industrial chain of medical biological functional coatings. It provides customers with a complete set of solutions including biological medical coating solution, coating equipment and process, product quality inspection and evaluation instruments and methods with multiple functions such as super lubrication, anticoagulant, antibacterial and antifouling, which are applicable to various medical devices. Existing main products: hydrophilic coating / super lubricating coating, anticoagulant coating and antibacterial coating. The company focuses on innovative research and development of biomaterial surface modification technology, and the development of high-end functional coating products with independent intellectual property rights and international competitiveness.
Since its establishment in 2017, BSF has established the first professional technical service platform covering the whole industrial chain of medical functional coatings in China, breaking the foreign technology monopoly, filling a number of gaps in China and successfully realizing import substitution, taking the complete set of solutions for surface coating technology of implant intervention medical devices with high technical threshold as the starting point. At present, it has served dozens of domestic medical device enterprises and groups.
Dr. Chen Miao, CO head of Huatai zijinda health fund, said: “BSF is a rare platform enterprise of biomaterial surface and interface modification technology in China. The team members with the founder Professor Chen Hong as the core have deeply cultivated biomaterial surface and interface modification technology for many years and established an industry-leading biomaterial surface and interface technology system and comprehensive R & D service platform. The company’s technology has successfully realized the commercial application and import substitution of a variety of products in the field of medical devices, filled a number of gaps in China and provided a better service for the future To meet clinical needs and provide perfect solutions. At the same time, the company’s technology has also shown great development potential in other life and health related industries. “
For more project information, please go to “Rui animal analysis”.